EFPIA

I want the people that make the medicines my family uses and the people that prescribe them to have a strong, productive and ethical relationship. To me it seems entirely sensible that there is an open exchange of information between the scientists and experts that spend years developing a new medicine and the clinicians that will make decisions on our treatment. It is a critical relationship and one that has delivered much for many over the years. It is also a relationship that is changing constantly. In recent years, companies have placed less emphasis on sales representatives and calls, instead …

The pharma industry is just months away from laying bare its relationships with doctors in Europe, revealing for the first time the names of doctors, how much individual pharma companies have paid them, and for what. From 30 June 2016, all pharmaceutical companies will be required to publish payments made in the previous year to doctors, nurses, and other healthcare professionals (HCPs), and identify them by name wherever possible. The new rules will also include payments to hospitals and other healthcare organisations (HCOs) across 33 European countries. Not surprisingly, there are some worries about what will happen in June: will …

Frank Hernandez, directeur associé de Market iT et membre du Think Tank Loi Bertrand, vous présente le Disclosure Code adopté par l’association européenne des entreprises de génériques. L’EGA (European Generic and biosimilar medicines Association) a adopté le 15 Janvier dernier un Disclosure Code assez similaire à celui adopté par l’EFPIA, avec néanmoins quelques différences. Ce Disclosure Code impose aux membres de l’EGA (adhérents directs ou adhérents via leur association locale comme le GEMME en France) de publier les transferts de valeurs directs et indirects avec les HCO et les HCP, hors dépenses de repas et boissons comme pour l’EFPIA, mais …

Selon une enquête réalisée par Veeva Systems en 2015, plus de 60% des entreprises de l’industrie pharmaceutique ne sont pas complètement prêtes à répondre aux exigences de transparence de l’EFPIA. En Juin 2016, tous les laboratoires pharmaceutiques dans les pays membres de l’EFPIA, la Fédération européenne des associations et industries pharmaceutiques, devront publier leurs transferts de valeurs aux professionnels et organismes de santé : les frais d’inscription, d’hospitalité et d’honoraires des consultants, les dons et des subventions… La première publication sera faite le 30 Juin 2016 pour les paiements effectués en 2015. Cette information sera publiée sur une plate-forme publique, …

The very best clinical practice does not take place in a vacuum. It requires input and expertise from many groups: clinicians; patient organisations; academics; healthcare organisations; and the manufacturers of new medicines and medical technology. Collaboration between my industry and these important customers results in three main benefits: 1. Making new medicines possible in the first place; 2. Providing vital health education needed to ensure that medicines are used appropriately; and 3. Capturing patient insights into current treatments and understanding unmet medical needs. The adoption of the EFPIA Healthcare Professional (HCP)/Healthcare Organisation (HCO) Disclosure Code will deliver long awaited financial …

The European Pharmaceutical Industry Association (EFPIA) has preempted government sunshine regulations in Europe by providing a holistic approach to disclosing transfers of value between healthcare professionals (HCPs) and organizations (HCOs) for its 40+ members in 33+ countries. In 2016, EFPIA members will have to publicly disclose any transfer of value captured in 2015 on a per country basis. As a part of this process, EFPIA country member associations will have to ensure that standard EFPIA requirements conform to state or local data privacy regulations. To read the article by Véronique Monjardet